Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors

Recruiting

Phase 1

STI-6643Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors

Sponsor:

Sorrento Therapeutics, Inc.

Code:

NCT04900519

Conditions

Solid Tumor

Relapsed Solid Neoplasm

Refractory Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

STI-6643

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-09. This information was provided to ClinicalTrials.gov by Sorrento Therapeutics, Inc. on 2023-01-17.